Drugs / CAB
re-read 9 days ago

CAB

Developed for
HIV infectious disease
Investigated by
ViiV Healthcare

Trials 1

202720282029203020312032
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07816250 Oct 2026 → Jun 2032 expected HIV infectious disease ViiV Healthcare Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CAB ClinicalTrials.gov intervention name — accepted as the source's own label NCT07816250 ↗